CD22 Dual-Target & Universal CAR-T: Overcoming CD19 Resistance with Next-Generation Approaches
For comprehensive information on CD19 CAR‑T therapy, see CD19 CAR‑T. For how CAR‑T cells work, visit our CAR‑T Cell Therapy Hub.
⚠️ Evidence Level Notice — Please Read Before Proceeding
CD22-directed and dual-target (CD19/CD22) CAR‑T therapies, as well as universal (allogeneic) CAR‑T products, currently have NO regulatory approval (FDA, EMA, or NMPA) in any jurisdiction. All patient access is exclusively through clinical trials. Results from early‑phase studies may not be reproducible in routine clinical practice. This page describes investigational approaches, not established treatments.
1. Why CD22? The Scientific Rationale for a Second Target
The Clinical Problem: CD19‑Negative Relapse
CD19‑directed CAR‑T therapy has transformed outcomes for B‑cell malignancies, but a significant challenge remains: antigen escape. In approximately 30‑50% of patients who initially respond to CD19 CAR‑T but later relapse, the cancer cells have lost CD19 expression on their surface, rendering the CAR‑T cells unable to recognize and attack them.
This is not treatment failure in the traditional sense — the CAR‑T cells may still be present and functional, but they're "blind" to cancer cells that no longer express CD19.
Why CD22?
CD22 (Siglec‑2) is a B‑cell‑restricted inhibitory receptor that, like CD19, is expressed throughout B‑cell development. Critically:
- CD22 is often retained on cancer cells even after they lose CD19
- CD22 expression is observed in >90% of B‑cell malignancies (B‑ALL, DLBCL, CLL, etc.)
- CD22 is internalized upon antibody binding, making it an attractive target for antibody‑drug conjugates and CAR‑T therapy
- CD22 is not expressed on hematopoietic stem cells, allowing for potential B‑cell recovery post‑treatment
- Unlike CD19, which has been the primary CAR‑T target for over a decade, CD22 represents a salvage target — a way to treat patients whose cancer has evolved to escape CD19‑directed therapy.
- CD22 is particularly valuable for patients with:
- Prior CD19 CAR‑T therapy with subsequent CD19‑negative relapse
- High‑risk disease where antigen escape is anticipated
- Combination strategies to prevent resistance
2. Dual‑Target (CD19/CD22) CAR‑T: The Logic of Simultaneous Targeting
Why Target Both CD19 and CD22?
The rationale is straightforward: reduce the probability of antigen escape. If cancer cells must lose BOTH CD19 AND CD22 to evade CAR‑T cells, the likelihood of escape is dramatically reduced.
Biological Advantages
- Redundancy: If one target is lost, the other remains
- Synergy: Dual signaling may enhance CAR‑T persistence and cytotoxicity
- Prevention: May delay or prevent relapse in high‑risk patients
Construct Designs Under Investigation
- Tandem CARs: Single CAR construct with both CD19 and CD22 scFv domains
- Bispecific CARs: CAR‑T cells expressing two separate CARs (one anti‑CD19, one anti‑CD22)
- Combination therapy: Co‑administration of separate CD19 and CD22 CAR‑T cell products
3. Universal (Allogeneic) CAR‑T: "Off‑the‑Shelf" Availability
The Limitation of Autologous CAR‑T
All currently approved CAR‑T products (Kymriah, Yescarta, Tecartus, Breyanzi) are autologous — made from the patient's own T‑cells. This creates significant challenges:
- Manufacturing time: 3‑4 weeks from collection to infusion
- Product failure: In 5‑15% of cases, insufficient T‑cells are collected or manufacturing fails
- T‑cell quality: Patients with heavily pretreated disease may have poor‑quality T‑cells
- Cost: Custom manufacturing for each patient is expensive ($300,000‑$500,000+)
- Access: Limited to certified centers with apheresis capabilities
The Universal CAR‑T Solution
Universal (allogeneic) CAR‑T cells are derived from healthy donors, modified to reduce rejection risk, and administered as "off‑the‑shelf" products. Key features:
- Immediate availability: No manufacturing wait time
- Standardized product: Consistent quality across patients
- Scalability: One donor can potentially treat multiple patients
- Lower cost: Elimination of patient‑specific manufacturing
- Broader access: Potentially available at more treatment centers
- Graft‑versus‑host disease (GVHD): Donor T‑cells may attack patient tissues
- Host‑versus‑graft rejection: Patient immune system may reject donor cells, limiting persistence
- Gene editing required: To reduce GVHD and rejection, universal CAR‑T products typically require:
- TCR knockout (e.g., TRAC gene deletion) to prevent GVHD
- HLA class I knockout (e.g., B2M deletion) to reduce rejection
- CD19/CD22 CAR insertion for target recognition
4. Investigational Products in Active Clinical Trials
No CD22‑directed, dual‑target, or universal CAR‑T product has received regulatory approval. The table below lists investigational constructs in active clinical development.
| Product / Construct | Developer | Target(s) | Type | Phase | ClinicalTrials.gov |
|---|---|---|---|---|---|
| GC012F (AZD0120) | Gracell / AstraZeneca | CD19 + BCMA (dual) | Autologous | Phase 1/2 | Search → |
| CT103A | CARsgen | CD19/CD22 (tandem) | Autologous | Phase 1/2 | Search → |
| ALLO‑329 | Allogene Therapeutics | CD19 | Universal (allogeneic) | Phase 1 | Search → |
| ALLO‑316 | Allogene Therapeutics | CD19 | Universal (allogeneic) | Phase 1 | Search → |
| UB‑VV100 | Umoja Biopharma | CD22 | Universal (allogeneic) | Phase 1 | Search → |
| Academic constructs | Multiple | CD22 or CD19/CD22 | Autologous / Universal | Phase 1 | Search CD22 CAR‑T → |
Clinical trial availability changes frequently. Always verify current status directly with ClinicalTrials.gov or the sponsor. This table is not exhaustive.
5. Level of Evidence — Explicit Comparison
CD22 and universal CAR‑T are at an earlier stage of clinical validation than CD19, BCMA, or other established targets.
| Target / Approach | Evidence Maturity | Regulatory Status | Data Horizon |
|---|---|---|---|
| CD19 (autologous) | Level 1 (Phase III, 8+ years) | FDA/EMA/NMPA approved | 2017–present |
| BCMA (autologous) | Level 1 (Phase III, 3+ years) | FDA/EMA approved | 2021–present |
| Claudin18.2 | Level 2‑3 (Phase 1/2) | No approval | 2019–present |
| GPC3 | Level 2‑3 (Phase 1/2) | No approval | 2020–present |
| CD22 (autologous) | Level 2‑3 (Phase 1/2, small cohorts) | No approval | 2018–present |
| CD19/CD22 dual | Level 2‑3 (Phase 1/2, early) | No approval | 2020–present |
| Universal CAR‑T (any target) | Level 2‑3 (Phase 1, very early) | No approval | 2019–present |
- CD22 CAR‑T data come primarily from Phase 1 dose‑escalation studies with limited patient numbers (typically <30‑50 patients)
- Dual‑target (CD19/CD22) data are even more limited, with most studies enrolling <20 patients
- Universal CAR‑T data are the most preliminary, with significant challenges in persistence and safety
- No randomized Phase III trials exist for any of these approaches
- Long‑term safety and efficacy data beyond 2‑3 years are not yet available
6. International Access Limitations — Honest Assessment
Access to CD22, dual‑target, and universal CAR‑T clinical trials is not guaranteed and is subject to strict eligibility criteria.
For CD22 CAR‑T (Autologous)
- Patients must have documented CD22 expression on tumor cells
- Most trials require prior CD19 CAR‑T therapy with subsequent relapse (CD19‑negative or CD19‑low)
- Adequate T‑cell collection is required (similar to autologous CD19 CAR‑T)
- Trials are predominantly in the US, China, and Europe
For Dual‑Target (CD19/CD22) CAR‑T
- Similar eligibility to autologous CD19 CAR‑T
- May include patients without prior CAR‑T therapy (as frontline or consolidation)
- Limited number of active trials
For Universal (Allogeneic) CAR‑T
- No requirement for patient T‑cell collection (major advantage)
- May be suitable for patients with poor T‑cell quality
- Lymphodepletion may be more intensive to prevent graft rejection
- Risk of GVHD requires careful monitoring
- Trials are concentrated in the US (Allogene, Caribou, others)
Common Eligibility Criteria Across All Approaches
- ECOG performance status 0‑1 (good functional status)
- Adequate cardiac, pulmonary, hepatic, and renal function
- No active CNS involvement (in most trials)
- No active infections or uncontrolled comorbidities
- Trials are conducted at specific academic centers
- International patients must travel to and remain near the trial site for 1‑3 months minimum
- No guarantee of enrollment even if eligible
For patients considering international clinical trials: Our platform can facilitate secure transfer of medical records for trial screening, but we cannot pre‑approve eligibility or guarantee enrollment. All decisions are made by trial investigators based on their specific protocol requirements.
7. Comparison: CD22, Dual‑Target, and Universal Approaches
| Feature | CD22 CAR‑T (Autologous) | CD19/CD22 Dual CAR‑T | Universal CAR‑T (Any Target) |
|---|---|---|---|
| Primary Use Case | CD19‑negative relapse after prior CAR‑T | Prevention of antigen escape | Immediate availability, poor T‑cell quality |
| Manufacturing | Patient's own cells (3‑4 weeks) | Patient's own cells (3‑4 weeks) | Donor cells (available immediately) |
| Target | CD22 only | CD19 + CD22 | CD19, CD22, or other |
| GVHD Risk | None (autologous) | None (autologous) | Present (requires gene editing) |
| Host Rejection | Not applicable | Not applicable | Present (limits persistence) |
| Evidence Level | Phase 1/2 | Phase 1/2 | Phase 1 |
| Regulatory Status | Investigational | Investigational | Investigational |
Medical Disclaimer: CancerCareE is an independent platform for patient information and introduction. It is not a healthcare provider. All medical decisions are made by licensed physicians.
Legal Framework •
Financial Transparency •
CAR‑T Hub